A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter

Cancer Research

Volumn 65, Issue 1, 2005, Pages 46-53

  Liu, Wanqing ^a   Innocenti, Federico ^a,b,d   Wu, Michael H ^a   Desai, Apurva A ^a,b   Dolan, M Eileen ^a,b,c,d   Cook Jr , Edwin H ^a,b,d   Ratain, Mark J ^a,b,d  

^a Department of Medicine ^*  (United States)

^b Department of Medicine   (United States)

^c Comm Clin Pharmacol/Pharmacogen ^*  (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSCRIPTION FACTOR SP1;

ALLELE; ARTICLE; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; DNA POLYMORPHISM; EMBRYO; FIBROBLAST; GEL MOBILITY SHIFT ASSAY; GENE ACTIVITY; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; INHERITANCE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

BASE SEQUENCE; CELL LINE, TUMOR; CONSENSUS SEQUENCE; CONTINENTAL POPULATION GROUPS; DNA PRIMERS; DNA-BINDING PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); PROTEIN KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFECTION;

EID: 11244319884     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Grandis JR, Sok JC, Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004;102:37-46.
2. Weiss WA, Burns MJ, Hackett C, et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 2003;63:1589-95.
3. Brandt R, Eisenbrandt R, Leenders F. et al. Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 2000;19:2129-37.
4. Brandt B, Hermann S, Straif K, Tidow N, Buerger H, Chang-Claude J. Modification of breast cancer risk in young women by a polymorphic sequence in the EGFR gene. Cancer Res 2004;64:7-12.
5. Ishii S, Xu YH, Stratton RH, Roe BA, Merlino GT, Pastan I. Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene. Proc Natl Acad Sci U S A 1985;82:4920-4.
6. Johnson AC, Ishii S, Jinno Y, Pastan I, Merlino GT. Epidermal growth factor receptor gene promoter. Deletion analysis and identification of nuclear protein binding sites. J Biol Chem 1988;263:5693-9.
7. McInerney JM, Wilson MA, Strand KJ, Chrysogelos SA. A strong intronic enhancer element of the EGFR gene is preferentially active in high EGFR expressing breast cancer cells. J Cell Biochem 2001;80:538-49.
8. Maekawa T, Imamoto F, Merlino GT, Pastan I, Ishii S. Cooperative function of two separate enhancers of the human epidermal growth factor receptor proto-oncogene. J Biol Chem 1989;264:5488-94.
9. Kageyama R, Merlino GT, Pastan I. Epidermal growth factor (EGF) receptor gene transcription: requirement for Sp1 and an EGF receptor-specific factor. J Biol Chem 1988;263:632936.
10. Nishi H, Senoo M, Nishi KH, et al. p53 Homologue p63 represses epidermal growth factor receptor expression. J Biol Chem 2001;276:41717-24.
11. Nishi H, Nishi KH, Johnson AC. Early growth response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. Cancer Res 2002;62:827-34.
12. Gonzalez EA, Disthabanchong S, Kowalewski R, Martin KJ. Mechanisms of the regulation of EGF receptor gene expression by calcitriol and parathyroid hormone in UMR 106-01 cells. Kidney Int 2002;61:1627-34.
13. Kageyama R, Merlino GT. Pastan I. A transcription factor active on the epidermal growth factor receptor gene. Proc Natl Acad Sci U S A 1988;85:5016-20.
14. Chen LL, Clawson ML, Bilgrami S, Carmichael GA. sequence-specific single-stranded DNA-binding protein that is responsive to epidermal growth factor recognizes an S1 nuclease-sensitive region in the epidermal growth factor receptor promoter. Cell Growth Differ 1993;4:975-83.
15. Hou X, Johnson AC, Rosner MR. Induction of epidermal growth factor receptor gene transcription by transforming growth factor β1: association with loss of protein binding to a negative regulatory element. Cell Growth Differ 1994;5:801-9.
16. Hou X, Johnson AC, Rosner MR. Identification of an epidermal growth factor receptor transcriptional repressor. J Biol Chem 1994;269:4307-12.
17. Kageyama R, Pastan I. Molecular cloning and characterization of a human DNA binding factor that represses transcription. Cell 1989:59:815-25.
18. Kageyama R, Merlino GT, Pastan I. Nuclear factor ETF specifically stimulates transcription from promoters without a TATA box. J Biol Chem 1989;264:15508-14.
19. Reed AL, Yamazaki H, Kaufman JD, Rubinstein Y, Murphy B, Johnson AC. Molecular cloning and characterization of a transcription regulator with homology to GC-binding factor. J Biol Chem 1998;273:21594-602.
20. Wilson MA, Chrysogelos SA. Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells. J Cell Biochem 2002;85:601-14.
21. Xu J, Thompson KL, Shephard LB, Hudson LG, Gill GN. T3 receptor suppression of Sp1-dependent transcription from the epidermal growth factor receptor promoter via overlapping DNA-binding sites. J Biol Chem 1993;268:16065-73.
22. 1 cell cycle phase specific transcription factor in epithelial cells. Oncogene 2002;21:1485-92.
23. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999;274:13176-80.
24. Buerger H. Gebhardt F, Schmidt H, et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 2000;60:854-7.
25. Liu W, Innocenti F, Chen P, Das S, Cook EH Jr, Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003;9:1009-12.
26. Courey AJ, Tjian R. Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell 1988;55:887-98.
27. Baseggio L, Bartholin L, Chantome A, Charlot C, Rimokh R, Salles G. Allele-specific binding to the -308 single nucleotide polymorphism site in the tumour necrosis factor-α promoter. Eur J Immunogenet 2004;31:15-9.
28. Gazzoli I, Kolodner RD. Regulation of the human MSH6 gene by the Sp1 transcription factor and alteration of promoter activity and expression by polymorphisms. Mol Cell Biol 2003;23:7992-8007.
29. Harendza S, Lovett DH, Panzer U, Lukacs Z, Kuhnl P, Stahl RA. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem 2003;278:20490-9.
30. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003;63:812-6.
31. Mann V, Hobson EE, Li B, et al. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by effecting bone density and quality. J Clin Invest 2001;107:899-07.
32. Dynan WS, Sazer S, Tjian R, Schimke RT. Transcription factor Sp1 recognizes a DNA sequence in the mouse dihydrofolate reductase promoter. Nature 1986;319:246-8.
33. Vallian S, Chin KV, Chang KS. The promyelocytic leukemia protein interacts with Sp1 and inhibits its transactivation of the epidermal growth factor receptor promoter. Mol Cell Biol 1998;18:7147-56.
34. Perea S, Oppenheimer D, Amador M, et al. Proceedings of American Society of Clinical Oncology, abstract 3005. Genotypic bases of EGFR inhibitors pharmacological actions. J Clin Oncol 2004;22.
35. Haley J, Whittle N, Bennet P, Kinchington D, Ullrich A. Waterfield M. The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription. Oncogene Res 1987;1:375-96.
36. Merlino GT, Ishii S, Whang-Peng J, et al. Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol Cell Biol 1985;5:1722-34.
37. Merlino GT, Xu YH, Richert N, et al. Elevated epidermal growth factor receptor gene copy number and expression in a squamous carcinoma cell line. J Clin Invest 1985;75:1077-9.
38. Glover KY, Perez-Soler R, Papadimitradopoulou VA. A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer. Semin Oncol 2004;31:83-92.
39. Kim ES, Vokes EE, Kies MS. Cetuximab in cancers of the lung and head & neck. Semin Oncol 2004;31:61-7.
40. Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 2004;30:1-17.
41. Lu C. Speers C, Zhang Y, et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 2003;95:1825-33.
42. Desai AA, Innocenti F, Ratain MJ. Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene 2003;22:6621-8.
43. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
44. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
45. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-11.
46. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.
47. Lee JW, Soung YH, Kim SY, et al. Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int J Cancer 2004. Epub ahead of print.
48. Arteaga CL. Selecting the right patient for tumor therapy. Nat Med 2004;10:577-8.
49. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7.
50. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Huntingt) 2003;17:23-8.